University of Wollongong
Browse

Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment

Download (531.72 kB)
journal contribution
posted on 2024-11-16, 07:13 authored by Jiamei LianJiamei Lian, Xu-Feng HuangXu-Feng Huang, Nagesh PaiNagesh Pai, Chao DengChao Deng
Olanzapine is the one of first line antipsychotic drug for schizophrenia and other serious mental illness. However, it is associated with troublesome metabolic side-effects, particularly body weight gain and obesity. The antagonistic affinity to histamine H1 receptors (H1R) of antipsychotic drugs has been identified as one of the main contributors to weight gain/obesity side-effects. Our previous study showed that a short term (2 weeks) combination treatment of betahistine (an H1R agonist and H3R antagonist) and olanzapine (O+B) reduced (−45%) body weight gain induced by olanzapine in drug-naïve rats. A key issue is that clinical patients suffering with schizophrenia, bipolar disease and other mental disorders often face chronic, even life-time, antipsychotic treatment, in which they have often had previous antipsychotic exposure. Therefore, we investigated the effects of chronic O+B co-treatment in controlling body weight in female rats with chronic and repeated exposure of olanzapine. The results showed that co-administration of olanzapine (3 mg/kg, t.i.d.) and betahistine (9.6 mg/kg, t.i.d.) significantly reduced (−51.4%) weight gain induced by olanzapine. Co-treatment of O+B also led to a decrease in feeding efficiency, liver and fat mass. Consistently, the olanzapine-only treatment increased hypothalamic H1R protein levels, as well as hypothalamic pAMPKα, AMPKα and NPY protein levels, while reducing the hypothalamic POMC, and UCP1 and PGC-1α protein levels in brown adipose tissue (BAT). The olanzapine induced changes in hypothalamic H1R, pAMPKα, BAT UCP1 and PGC-1α could be reversed by co-treatment of O+B. These results supported further clinical trials to test the effectiveness of co-treatment of O+B for controlling weight gain/obesity side-effects in schizophrenia with chronic antipsychotic treatment.

Funding

Schizophrenia: Reversal of atypical antipsychotic drug-induced obesity and its related metabolic disorders

National Health and Medical Research Council

Find out more...

DECISION SUPPORT FOR CLIMATE CHANGE ADAPTATION IN CALIFORNIA'S MONTANE ECOSYSTEMS

National Institute of Food and Agriculture

Find out more...

History

Citation

Lian, J., Huang, X., Pai, N. & Deng, C. (2014). Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment. PLoS One, 9 (8), e104160-1-e104160-11.

Journal title

PLoS ONE

Volume

9

Issue

8

Language

English

RIS ID

92424

Usage metrics

    Categories

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC